Search Bar & Filters
Found 18 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.
Actively Recruiting
Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.
Actively Recruiting
Researchers are studying the clinical and health outcomes of amivantamab-containing treatments for people with common EGFR-mutated advanced non-small cell lung cancer NSCLC. NSCLC is the most common type of lung cancer and can spread to other parts of the body. This observational study looks at how these treatments work in real-world clinical settings for patients with specific EGFR mutations. Participants include those with advanced NSCLC who have EGFR exon 19 deletions or exon 21 L858R mutations. Two groups are observed one receiving amivantamab combined with carboplatin and pemetrexed after previous therapy failure, and another receiving amivantamab with lazertinib as first-line treatment. No study drugs are provided data is collected from routine medical care. During the study, researchers collect data on treatment duration, progression-free survival, overall survival, adverse events, dose changes, and medication use for up to about 60 months. Quality of life is assessed using the SKINDEX and EORTC QLQ-C30 questionnaires. The study tracks how patients respond to treatment and monitors safety outcomes, with participation lasting several years.
Actively Recruiting
Researchers are studying how well Immune Globulin Infusion IGI, 10% can help prevent infections in adults with multiple myeloma who are receiving a special bispecific antibody therapy targeting B-cell maturation antigen BCMA and CD3. The trial compares two groups one receiving IGI, 10% regularly for 12 months as primary infection prevention, and the other receiving IGI, 10% only if they develop a serious infection during the study period. This is a Phase 3, randomized, open-label study sponsored by Takeda. Participants will be randomly assigned to either receive IGI, 10% intravenously every 3 or 4 weeks for 12 months regardless of infections or receive it only after experiencing at least one serious infection during the 12-month observation. The dosing is based on standard care, with a dose of 400 mgkg given within 3 days after randomization. The study design includes 15 to 19 clinic visits depending on dosing intervals. During the study, participants will be monitored for serious infections and other infection-related outcomes up to 12 months. Researchers will measure the time to first serious infection as the primary outcome, along with rates of infections, antibiotic use, hospitalizations, and immune response markers such as immunoglobulin G levels. Safety will also be assessed by tracking adverse events related to IGI, 10%. Total participation lasts up to 14 months including an approximately 8-week screening period.
Actively Recruiting
Researchers are evaluating mavorixafor, a drug being studied for people aged 12 and older who have congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders. These conditions cause low neutrophil levels and lead to recurrent or serious infections. The study aims to show if mavorixafor can improve clinical outcomes and increase neutrophil counts, while also assessing its safety and tolerability. Participants will continue their current treatment during the study, which may include therapies like granulocyte-colony stimulating factor G-CSF, immunoglobulin replacement, antibiotics, or no active treatment. They will be randomly assigned to receive either mavorixafor or a placebo orally once daily for up to 52 weeks. The study uses a quadruple-blind design to compare these groups in parallel. During the trial, participants will have regular assessments to monitor infection rates and severity, neutrophil counts, antibiotic use, oral ulcers, and fatigue levels using questionnaires. An independent committee will review infections to ensure accuracy. Safety and treatment effects will be followed throughout the 52-week treatment period. The total participation may last until the study ends in late 2027.
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.
Actively Recruiting
Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.
Actively Recruiting
Researchers are evaluating the effects of BAY 3670549 in adults with atrial fibrillation who require electrical cardioversion. The study aims to understand how well BAY 3670549 works to restore normal heart rhythm, how safe and tolerable it is, and how the body processes this medicine. Participants will receive either BAY 3670549 or a placebo to compare outcomes. Each participant will receive a single intravenous infusion of BAY 3670549 or a placebo. After this, researchers will observe whether the heart rhythm returns to normal without needing electrical cardioversion. If the heart rhythm does not revert, electrical cardioversion can still be performed as planned. The study measures how many participants convert to normal rhythm and how quickly, as well as any medical issues after treatment and the medicines pharmacokinetics. Participants will be involved for up to two months. During this time, their heart rhythm will be closely monitored, and safety assessments for any adverse events will be conducted up to 48 hours after treatment. Blood samples will be taken to measure the medicine concentration. The primary outcome is the number of participants whose heart rhythm converts to normal within 3 hours without additional treatment, providing important data on the treatments impact on atrial fibrillation.
Actively Recruiting
Researchers are evaluating the investigational medicine BI 764524 for adults with moderate to severe non-proliferative diabetic retinopathy, an eye condition related to diabetes. The study aims to determine whether BI 764524 helps improve this condition and to identify the best treatment plan. This phase 2 trial randomly assigns participants to five groups to compare different dosing regimens and controls, including a group receiving aflibercept, an approved diabetic retinopathy treatment available only in the USA. Participants receive varying numbers of injections of BI 764524 in one eye over one year, with some visits involving sham injections that mimic the procedure without a needle to maintain blinding. One group receives only sham injections, and another group in the USA receives aflibercept or sham injections. The treatment period lasts 52 weeks, after which researchers evaluate improvements in eye severity and complications. Throughout the 1.5-year study, participants visit the study site at least 16 times for regular eye exams, vision tests, and imaging scans to monitor the eye condition and treatment effects. Researchers assess improvements using the Diabetic Retinopathy Severity Scale and watch for vision-threatening complications. Safety is monitored by tracking any adverse effects. The study helps understand how BI 764524 affects diabetic retinopathy over time.
Actively Recruiting
Researchers are studying evorpacept combined with trastuzumab and chemotherapy in people with metastatic HER2-positive breast cancer who have previously been treated with trastuzumab-deruxtecan. This Phase 2, single-arm, multicenter study aims to evaluate the effectiveness, safety, and tolerability of this combination treatment. The study is part of a larger master protocol exploring evorpacept in various cancers, but currently only the breast cancer substudy is open. Participants receive evorpacept and trastuzumab through intravenous infusions every three weeks. Alongside these, they receive one chemotherapy drug chosen by their physician, which may be capecitabine oral, eribulin, gemcitabine, paclitaxel, or vinorelbine, each given on specific schedules. Treatment continues until disease progression, unacceptable side effects, participant choice, investigator decision, or study end. During the study, participants undergo regular assessments to monitor tumor response using RECIST v1.1 criteria, safety evaluations including adverse event tracking and lab tests, and drug level measurements. The main outcome is overall response rate about six months after the last participant is enrolled. The total participation duration varies depending on treatment continuation and disease status, with close follow-up during and after treatment.
1-10 of 18
1